Allscripts price target raised to $23 from $18 at Leerink Leerink raised its price target for Allscripts shares to $23 saying the company reported a high quality Q4 with bookings well ahead of expectations. The firm keeps an Outperform rating on the stock.
Allscripts takes $200M equity position in NantHealth Allscripts announced they have taken a significant step forward in their strategic partnership through two cross-investments and a strengthening of their commercial agreement. The investments include Allscripts' purchase of a 10% equity stake in NantHealth for $200M in cash. In addition, NantCapital, LLC, the personal investment vehicle of Dr. Patrick Soon-Shiong, founder of NantHealth, has made a $100M investment into Allscripts.